Physician

David Young Kahn, M.D.

According to 2025 Medicare claims, David Kahn, M.D. (NPI: 1942421334) practices hematology/oncology in the Phoenix-Mesa-Chandler, AZ market, with the plurality of this provider's patient population coming from Maricopa, AZ. This provider's primary affiliated billing organization is AMERICAN ONCOLOGY PARTNERS PA (NPI: 1265929723; TIN: 824681345) and primary practice location at 85374-7281. Kahn is affiliated with the Caravan Health ACO 50 LLC (ACO ID: A5160), participating under the MSSP model.

Kahn's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 873 traditional Medicare patients, billed 239,925 HCPCS/CPT codes, and received $3,421,189 in Medicare payments. The top billing code was 99223 (Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes). Part D data shows 1,115 prescription claims across 247 beneficiaries totaling $6,758,540 in drug costs, led by Revlimid (Lenalidomide). 2021 DME data shows 12 claims. Open Payments data shows 279 records totaling $7,986. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $1,155,034 to $3,421,189. Similarly, Part D prescription costs have risen steadily, from $762,620 to $6,758,540. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	589	144,238	$1,155,034
2016	631	157,833	$1,496,166
2017	665	159,628	$1,532,794
2018	617	131,375	$1,299,925
2019	662	165,371	$2,126,479
2020	665	147,700	$2,262,524
2021	656	193,125	$2,141,572
2022	697	209,029	$2,693,571
2023	818	251,586	$3,396,802
2024	873	239,925	$3,421,189

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	171	793	$762,620
2016	187	875	$1,542,842
2017	218	1,074	$3,051,002
2018	234	1,161	$3,546,514
2019	226	1,090	$3,533,628
2020	221	1,182	$3,759,071
2021	196	990	$3,431,353
2022	216	1,008	$3,660,182
2023	242	1,046	$4,266,705
2024	247	1,115	$6,758,540

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	119	$16,671
2016	12	145	$21,737
2017	N/R	82	$9,195
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	14	$267
2021	N/R	12	$3,431
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	237	274	$132
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	702	2,211	$93
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	205	832	$60
36415	Insertion of needle into vein for collection of blood sample	643	1,905	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	569	1,890	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	110	3,073	$1,902,317
Zejula	Niraparib Tosylate	30	900	$522,055
Brukinsa	Zanubrutinib	34	1,020	$485,374
Imbruvica	Ibrutinib	30	840	$439,531
Xtandi	Enzalutamide	32	960	$438,059

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	279	$7,986	Karyopharm Therapeutics Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for David Young Kahn, M.D.?

Tedicare shows public-source Medicare data for David Young Kahn, M.D. (NPI 1942421334), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does David Young Kahn, M.D. have ACO affiliation data?

David Young Kahn, M.D. is shown with ACO affiliation data for Caravan Health ACO 50 LLC (MSSP, ACO ID A5160).

What billing organization is linked to David Young Kahn, M.D.?

David Young Kahn, M.D. is linked to AMERICAN ONCOLOGY PARTNERS PA (billing NPI 1265929723) in the available physician profile data.

Does David Young Kahn, M.D. have Open Payments data?

David Young Kahn, M.D. has 279 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.